Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelion Therapeutics Announces Leadership Change
Novelion General Counsel Benjamin Harshbarger Appointed as Interim Chief Executive Officer (CEO) VANCOUVER, British Columbia , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN), today announced that General Counsel, Benjamin Harshbarger , has been appointed as interim CEO,
View HTML
Toggle Summary Novelion Therapeutics Reports Third Quarter 2018 Financial Results
VANCOUVER, British Columbia , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”), today reported financial results for
View HTML
Toggle Summary Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update
- New Aegerion loan facility, provided by existing bondholders, strengthens balance sheet and is expected to provide bridge to a potential comprehensive long-term capital restructuring - Company expects to achieve positive cash flow at Aegerion level by 2Q 2019 on full-year net product sales of
View HTML
Toggle Summary Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today its observance of The FH Foundation’s
View HTML
Toggle Summary Novelion Therapeutics Announces Next Phase of Operational Improvements
Once fully implemented, plans expected to reduce annual costs by approximately $35 million VANCOUVER, British Columbia , Aug. 23, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with
View HTML
Toggle Summary Novelion Therapeutics Reports Second Quarter 2018 Financial Results
Following recent marketing approval in both generalized and partial lipodystrophy indications, European launch of MYALEPTA® has commenced VANCOUVER, British Columbia , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing
View HTML
Toggle Summary Novelion Therapeutics Announces Marketing Authorization for MYALEPTA® (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy
MYALEPTA is the first approved therapy in Europe indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients VANCOUVER, British Columbia , July 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.
View HTML
Toggle Summary Novelion Therapeutics Appoints Mark Corrigan, M.D. as Executive Chair of the Board of Directors
Chief Operating Officer Jeff Hackman Appointed as Interim Chief Executive Officer (CEO) VANCOUVER, British Columbia , July 03, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN) today announced that Mark Corrigan , M.D. has been appointed as Executive Chair of the Board of
View HTML
Toggle Summary Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions
Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels Company plans to initiate Phase 2 proof of concept study in hypoleptinemic metabolic disorder (HMD) by year-end VANCOUVER, British Columbia , June 25, 2018 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
Europe represents potentially the largest market for metreleptin with expected authorization in both generalized and partial lipodystrophy VANCOUVER, British Columbia , June 01, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing
View HTML